The central obstacle, the authors explain, is heterogeneity. Oesophageal adenocarcinoma is driven in large part by chromosomal instability, a process that generates large-scale genomic chaos rather than the tidy, single-gene mutations seen in some other cancers. This instability produces profound differences not only between patients but also between different regions of the same tumour and between the primary tumour and its metastases. Two cells sitting centimetres apart within one patient’s oesophagus may carry different copy-number landscapes, different mutational burdens and different vulnerabilities. A therapy that eradicates one subclone may simply clear the way for another, which is why responses to treatment are so variable and why resistance so often emerges. Any model that smooths over this complexity risks giving clinicians a misleading picture of how a real tumour will behave.

Precision oncology promises to match each treatment to the biology of each tumour, but the review makes clear that in oesophageal cancer this promise has been constrained by history. Conventional two-dimensional cell lines—the workhorses of cancer biology for decades—grow quickly, are cheap and are easy to manipulate genetically, yet decades of passaging in plastic have driven them far from the tumours they originally came from. They lack the three-dimensional architecture of real tissue, they have lost most of the stromal and immune cells that surround a tumour in the body, and their genomes often no longer reflect the patient’s disease. They remain useful for dissecting mechanisms, the authors concede, but as avatars of an individual patient they fall short of what translational medicine now demands.

The models that have attracted the most excitement in recent years are patient-derived organoids: miniature, self-organising tumour fragments grown from fresh biopsy or surgical tissue in a supportive extracellular matrix. Because they are established directly from a patient and expanded for only a limited number of passages, organoids preserve much of the genotype and phenotype of the parent tumour, including the copy-number aberrations that dominate oesophageal adenocarcinoma. Crucially, they can be grown in multi-well formats, meaning dozens of drugs and drug combinations can be tested against a patient’s own tumour cells within days to weeks—a time horizon that can genuinely inform clinical decision-making. Studies across multiple cancer types have shown that organoid drug responses can predict patient responses with encouraging accuracy, and the review highlights their potential as functional biomarkers for treatment selection in oesophageal cancer specifically.

Yet organoids have an inherent limitation: they usually contain only the epithelial cancer cells. The tumour microenvironment—the fibroblasts, immune cells, blood vessels and signalling molecules that bathe a tumour in vivo—is largely absent, and it is this microenvironment that determines whether immunotherapies work. To close that gap, researchers are developing co-culture systems that introduce cancer-associated fibroblasts or immune cells into organoid cultures, and the review singles out immune-augmented organoid platforms as one of the most promising frontiers. By embedding tumour organoids with autologous immune cells, laboratories can begin to run functional immunology readouts: measuring whether a patient’s own T cells recognise their tumour, whether immune checkpoint blockade reinvigorates an anti-tumour response, and whether resistance mechanisms are already at play. Such systems offer a glimpse of personalised immunotherapy testing—something barely imaginable a decade ago.

At the other end of the biological fidelity spectrum sit patient-derived xenografts, or PDX models, in which fragments of a patient’s tumour are implanted into immunodeficient mice. These models retain the three-dimensional architecture, stromal interactions and evolutionary dynamics of the original tumour, and because they grow inside a living organism they capture whole-body pharmacology—how a drug is absorbed, distributed, metabolised and cleared—that no dish can replicate. Orthotopic variants, implanted directly into the oesophagus, add anatomical realism, while humanised PDX mice, engrafted with a human immune system, allow immunotherapies to be studied in a living setting. The trade-off, the authors stress, is throughput and time: establishing a PDX line takes months, success rates vary, and the cost and animal requirements limit how many patients can be modelled at scale. PDX models therefore serve best as deep characterisation platforms and for studying evolutionary and pharmacological questions rather than as rapid diagnostic tools.

Between the dish and the mouse lies a class of models that the review treats with particular attention: ex vivo organotypic tissue slice platforms and histocultures. Rather than dissociating a tumour or passaging it, these approaches take fresh slices of the actual surgical specimen—preserving the full cellular ecosystem of cancer cells, stroma, vasculature and immune infiltrate—and keep them alive in culture for days to a few weeks. Because nothing is disrupted, these slices offer what may be the highest fidelity to the parent tumour of any platform, and their short turnaround makes them attractive for clinically aligned endpoints such as predicting a patient’s response to neoadjuvant chemotherapy or radiotherapy before treatment begins. The limitations are equally practical: slice viability is finite, oxygen and nutrient penetration constrain slice thickness, and standardisation across laboratories remains immature. Nonetheless, the authors argue that organotypic cultures, especially when paired with immune readouts, occupy a unique translational niche for short-horizon therapeutic testing.

The review then turns to a rapidly accelerating dimension of cancer modelling that involves no cells at all: computation. In silico inference pipelines now integrate whole-genome sequencing, transcriptomics, epigenetics and imaging data to infer tumour evolutionary history, predict vulnerabilities and stratify patients, while computational histopathology—increasingly powered by deep learning applied to routine pathology slides—can extract prognostic and predictive information at a scale no experimental model can match. Digital approaches offer unlimited scalability and near-instant results, and they can integrate multi-omic and imaging information that fragmented experimental systems capture only in part. But the authors are emphatic about a caveat: algorithms trained on retrospective data are only as good as their validation, and rigorous benchmarking against real patient outcomes and against experimental models is essential before computational predictions can safely guide therapy. The most credible future, they suggest, is not a single winning platform but a triangulation in which genomic inference, organoid and slice-based drug testing, and selective PDX experiments corroborate one another.

What emerges from the survey is a portfolio philosophy. No single model satisfies all the translationally relevant criteria the authors apply—fidelity to the parent tumour, representation of stromal and immune compartments, scalability, time-to-result and suitability for clinically aligned endpoints such as response prediction and resistance evolution. Organoids win on speed and scalability; organotypic slices win on microenvironmental fidelity and clinical turnaround; PDX models win on organism-level pharmacology and evolutionary context; and computational pipelines win on throughput and data integration. Used intelligently and in combination, these platforms could finally give oncologists what oesophageal adenocarcinoma has long denied them: a way to test, in advance and in the laboratory, whether a given therapy will work for a given patient, and to watch resistance evolve before it happens in the clinic.

The stakes could hardly be higher. As immune checkpoint inhibitors reshape frontline treatment of gastro-oesophageal cancers and a growing arsenal of targeted agents waits in the wings, the absence of reliable predictive biomarkers means many patients endure toxic therapies from which they derive little benefit, while potentially effective options go untried. The Birmingham team, whose work was supported by Cancer Research UK and the Sir Arthur Thomson Charitable Trust, frames its review as both a critical appraisal and a call to action: the model-building tools now exist, but the field must invest in head-to-head comparisons, standardisation and prospective validation against patient outcomes. If that work succeeds, the era of treating oesophageal adenocarcinoma by trial and error could give way to one in which a patient’s tumour is first grown, challenged and computationally interrogated in the laboratory—so that the first real experiment happens where it matters most, in the clinic, with the odds stacked in the patient’s favour.

Subject of Research: Preclinical and computational modelling of oesophageal adenocarcinoma for precision oncology and immunotherapy

Article Title: Modelling oesophageal adenocarcinoma for precision oncology and immunotherapy

Article References: Anwar, R., Rose, E., Swirsky, F., Kunene, V., & Contino, G. (2026). Modelling oesophageal adenocarcinoma for precision oncology and immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04447-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04447-3

Keywords: oesophageal adenocarcinoma, tumour heterogeneity, patient-derived organoids, patient-derived xenografts, immunotherapy, precision oncology, drug sensitivity, tumour microenvironment, computational histopathology, chromosomal instability, personalised medicine, cancer models

Patient-derived xenografts, or PDX models, involve the implantation of human tumor tissues directly into immunodeficient mice. These models maintain the histological architecture and genetic makeup of the original tumors far better than traditional cell lines, offering a more clinically relevant arena for testing therapeutic agents. The Chinese research team capitalized on this technique by transplanting over 1,000 surgical and biopsy specimens from patients with various gastrointestinal malignancies, including ESCC, esophagogastric junction adenocarcinoma (EGJAC), and gastric adenocarcinoma (GAC), into NOD/SCID mice, which lack adaptive immunity.

Between January 2013 and August 2015, the researchers conducted a comprehensive engraftment campaign, implanting the fresh tumor tissues subcutaneously into specialized mice and meticulously documenting engraftment rates and tumor growth dynamics. A total of 208 xenograft models were successfully established, representing an overall engraftment rate of approximately 20.8%, a notable achievement given the inherent challenges in PDX formation, especially within gastrointestinal tumors renowned for their heterogeneity and aggressive nature.

Diving deeper into the types of cancers, ESCC exhibited the highest engraftment rate at 21.2%, substantiating its clinical significance within the Chinese demographic due to higher incidence rates. EGJAC and GAC followed with engraftment rates of 16.9% and 10.9%, respectively. These variances underscore the biological complexities and tumor microenvironment interactions unique to each cancer subtype, influencing successful xenografting.

The latency period, or the time taken for implanted tumors to grow sufficiently in mice, varied amongst the cancer types. For the initial passage, ESCC xenografts established within an average of approximately 76 days, whereas EGJAC and GAC showed longer latency periods of around 90 and 85 days, respectively. Interestingly, during the subsequent passage, these latency periods reduced significantly across all tumor types, averaging around 52 to 55 days. This observation suggests an adaptation process where tumor cells, once acclimatized to the murine environment, exhibit expedited growth kinetics in subsequent passages.

Beyond mere establishment rates, the study unearthed noteworthy correlations between clinical and pathological factors and successful engraftment. In ESCC cases, variables such as patient gender, the type of specimen (biopsy vs. surgical tissue), and tumor differentiation significantly influenced engraftment outcomes. In gastric adenocarcinoma, factors including patient age, specimen type, tumor differentiation, and Lauren classification—a histological subtype categorizing gastric tumors as intestinal or diffuse—played influential roles. Such nuanced understanding emphasizes the importance of patient and tumor characteristics in PDX success rates, potentially aiding future patient stratification for personalized models.

From a clinical perspective, the team monitored patients over extended periods—46 months for ESCC and 64 months each for EGJAC and GAC—shedding light on the prognostic implications of xenograft formation. Intriguingly, patients with gastric adenocarcinoma whose tumor tissues yielded successful xenografts showed significantly poorer survival compared to those whose tumors failed to engraft. This finding aligns with previous literature suggesting that aggressive tumor biology is more amenable to PDX establishment, thereby providing a dual opportunity to study both tumor aggressiveness and responsiveness.

The establishment of this Chinese PDX library holds immense promise beyond academic achievement. It offers a robust platform for preclinical drug evaluation that more faithfully mimics human tumor biology. By encompassing tumor types prevalent in the Chinese population, the repository addresses a significant gap in cancer research where most existing PDX models are derived from Western populations, potentially limiting translational applicability.

Moreover, this repository facilitates personalized oncology approaches by enabling drug sensitivity testing on patient-specific tumor models. This approach could refine treatment regimens and identify novel therapeutic targets, ultimately enhancing patient outcomes. The ability to predict clinical responses based on PDX testing could transform current cancer care paradigms from empirical treatment choices to biology-driven precision medicine.

Establishing and maintaining such a biobank require overcoming considerable technical and logistical challenges, including tissue procurement, handling, and engraftment consistency. The success rate reported in this study reflects rigorous methodological optimization and a sustained commitment to creating a high-quality resource. The researchers’ choice of NOD/SCID mice underscores the necessity of immunodeficient hosts to facilitate human tumor growth, eliminating confounding by host immune rejection.

As this PDX library expands, it opens avenues for collaborative research endeavors at both national and international levels. The availability of well-characterized, genomically annotated PDX models could accelerate the validation of molecular targets and the development of next-generation therapeutic agents tailored to tumor-specific vulnerabilities.

Furthermore, this initiative underscores the importance of integrating clinical annotations with experimental models. Matching PDX data with detailed patient clinical information enriches the translational value of findings and fosters the discovery of biomarkers predictive of treatment response or resistance.

While the current focus centers on gastrointestinal tumors—given their significant morbidity and mortality in China—the framework established by this research sets a precedent for creating PDX libraries from other cancer types, fostering a broader understanding of cancer heterogeneity and treatment resistance mechanisms.

In synthesizing these efforts, this study contributes substantially to the global oncology research infrastructure. It aligns with the growing consensus that high-fidelity preclinical models are paramount to overcoming the translational gap that has historically hindered effective drug development.

In conclusion, the establishment of a Chinese PDX library from gastrointestinal cancers signifies a milestone in personalized cancer research. By capturing the biological intricacies of predominant local tumor types, this resource empowers researchers and clinicians with refined tools for therapy development and individualized treatment decision-making. This endeavor not only enhances scientific understanding but also holds the potential to directly impact patient care, offering hope for improved survival outcomes in a cancer-burdened population.

Subject of Research: Establishment and characterization of a patient-derived xenograft (PDX) library from gastrointestinal cancers prevalent in China, including esophageal squamous cell carcinoma, esophagogastric junction adenocarcinoma, and gastric adenocarcinoma.

Article Title: Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers

Article References:
Liu, Y., He, W., Wu, Q. et al. Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers. BMC Cancer 25, 1508 (2025). https://doi.org/10.1186/s12885-025-14845-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14845-y